FDA approves first medication for chronic yeast infection

The FDA has approved VIVJOA — the first medication for recurrent vulvovaginal candidiasis — for use in permanently infertile and postmenopausal women, according to a Mycovia Pharmaceuticals press release.
The oteseconazole capsules are the first medication developed for the treatment of recurrent vulvovaginal candidiasis (RVVC), which is a specific form of VVC that is defined by the occurrence of three or more acute yeast infection episodes within 12 months.
VIVJOA has shown long-term efficacy in RVVC in three phase 3 trials, with the most common side effects being headache and

The FDA has approved VIVJOA — the first medication for recurrent vulvovaginal candidiasis — for use in permanently infertile and postmenopausal women, according to a Mycovia Pharmaceuticals press release.
The oteseconazole capsules are the first medication developed for the treatment of recurrent vulvovaginal candidiasis (RVVC), which is a specific form of VVC that is defined by the occurrence of three or more acute yeast infection episodes within 12 months.
VIVJOA has shown long-term efficacy in RVVC in three phase 3 trials, with the most common side effects being headache and